Antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST)

被引：0
|
作者：
Qiu, Haibo
Zhou, Zhi-Wei
Zhou, Ye
Wan, Xiangbin
Li, Ning
Tao, Kaixiong
Li, Yong
Wu, Xin
Chen, Zi
Liu, Lihui
Men, Lichuang
Wang, Hengbang
Liang, Eric
Wang, Cunlin
Jiang, Lixin
Yang, Dajun
Xu, Rui-Hua
Zhai, Yifan
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Henan Canc Hosp, Zhengzhou, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Med Coll, Wuhan, Peoples R China
[5] Guangdong Prov Peoples Hosp, Guangzhou, Peoples R China
[6] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[7] Ascentage Pharma Suzhou Co Ltd, Suzhou, Peoples R China
[8] Ascentage Pharma Grp Inc, Rockville, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11540
引用
收藏
页数：1
相关论文
共 33 条
  • [21] Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
    Jiang, Qian
    Li, Zongru
    Qin, Yazhen
    Li, Weiming
    Xu, Na
    Liu, Bingcheng
    Zhang, Yanli
    Meng, Li
    Zhu, Huanling
    Du, Xin
    Chen, Suning
    Liang, Yang
    Hu, Yu
    Liu, Xiaoli
    Song, Yongping
    Men, Lichuang
    Chen, Zi
    Niu, Qian
    Wang, Hengbang
    Lu, Ming
    Yang, Dajun
    Zhai, Yifan
    Huang, Xiaojun
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [22] Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
    Qian Jiang
    Zongru Li
    Yazhen Qin
    Weiming Li
    Na Xu
    Bingcheng Liu
    Yanli Zhang
    Li Meng
    Huanling Zhu
    Xin Du
    Suning Chen
    Yang Liang
    Yu Hu
    Xiaoli Liu
    Yongping Song
    Lichuang Men
    Zi Chen
    Qian Niu
    Hengbang Wang
    Ming Lu
    Dajun Yang
    Yifan Zhai
    Xiaojun Huang
    Journal of Hematology & Oncology, 15
  • [23] Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
    Qian Jiang
    Zongru Li
    Yazhen Qin
    Weiming Li
    Na Xu
    Bingcheng Liu
    Yanli Zhang
    Li Meng
    Huanling Zhu
    Xin Du
    Suning Chen
    Yang Liang
    Yu Hu
    Xiaoli Liu
    Yongping Song
    Lichuang Men
    Zi Chen
    Qian Niu
    Hengbang Wang
    Ming Lu
    Dajun Yang
    Yifan Zhai
    Xiaojun Huang
    Journal of Hematology & Oncology, 16
  • [24] Correlation of receptor tyrosine kinase (RTK) activity and apoptosis with response to sunitinib treatment in patients with gastrointestinal stromal tumor (GIST)
    Davis, D. W.
    McConkey, D. J.
    Heymach, J. V.
    Desai, J.
    George, S.
    DePrimo, S. E.
    Bello, C. L.
    Baum, C. M.
    Demetri, G. D.
    EJC SUPPLEMENTS, 2006, 4 (12): : 21 - 22
  • [25] Safety and Efficacy of HQP1351, a 3rd Generation Oral BCR-ABL Inhibitor in Patients with Tyrosine Kinase Inhibitor-Resistant Chronic Myelogenous Leukemia: Preliminary Results of Phase I Study
    Jiang, Qian
    Huang, Xiao Jun
    Chen, Zi
    Men, Lichuang
    Liu, Wei
    Sun, Xuemei
    Ji, Jiao
    Wang, Hengbang
    Hou, Yue
    Hu, Po
    Zou, Lei
    Yan, Hua
    Huang, Yingjie
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2018, 132
  • [26] Encouraging activity of novel pan-KIT and PDGFRa inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST)
    Janku, F.
    Razak, A. R. A.
    Gordon, M. S.
    Flynn, D.
    Kaufman, M.
    Pitman, J.
    Smith, B.
    Somaiah, N.
    Jennings, J.
    Salah, S.
    Westwood, D.
    Greensmith, D.
    Jacobson, J.
    Rosen, O.
    George, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Activity of AMN107, a novel kinase inhibitor, in gastrointestinal stromal tumor (GIST): Preclinical rationale and early clinical results with imatinib-resistant GIST.
    Demetri, GD
    Bauer, S
    Dileo, P
    van den Abbeele, A
    George, S
    Morgan, J
    Veronese, L
    Alland, L
    Massimini, G
    Salesi, J
    Quigley, MT
    Pokela, J
    Denise, C
    Manley, P
    Fletcher, JA
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9030S - 9030S
  • [28] Caregivers of patients receiving long-term treatment with a tyrosine kinase inhibitor (TKI) for gastrointestinal stromal tumour (GIST): a cross-sectional assessment of their distress and burden
    Langenberg, S. M. C. H.
    Reyners, A. K. L.
    Wymenga, A. N. M.
    Sieling, G. C. M.
    Veldhoven, C. M. M.
    van Herpen, C. M. L.
    Prins, J. B.
    van der Graaf, W. T. A.
    ACTA ONCOLOGICA, 2019, 58 (02) : 191 - 199
  • [29] Inhibition and flare patterns of metabolic response to the heat shock protein 90 (Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced gastrointestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor (TKI) therapy
    Van den Abbeele, A. D.
    Yap, J. T.
    Grayzel, D. S.
    Walker, J.
    Demetri, G. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 159, 2022)
    Jiang, Qian
    Li, Zongru
    Qin, Yazhen
    Li, Weiming
    Xu, Na
    Liu, Bingcheng
    Zhang, Yanli
    Meng, Li
    Zhu, Huanling
    Du, Xin
    Chen, Suning
    Liang, Yang
    Hu, Yu
    Liu, Xiaoli
    Song, Yongping
    Men, Lichuang
    Chen, Zi
    Niu, Qian
    Wang, Hengbang
    Lu, Ming
    Yang, Dajun
    Zhai, Yifan
    Huang, Xiaojun
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
1234